Overview

* Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln

* Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year

* Mirum updates 2025 revenue guidance to $500-$510 mln

Outlook

* Mirum updates 2025 revenue guidance to $500-$510 mln

* Company expects VISTAS study topline data in Q2 2026

* Mirum anticipates VANTAGE study data in first half of 2027

Result Drivers

* LIVMARLI SALES - LIVMARLI net product sales grew 56% over Q3 2024, contributing significantly to overall revenue growth

* BILE ACID MEDICINES - Bile Acid Medicines sales increased 31% over Q3 2024, supporting revenue growth

* PIPELINE PROGRESS - Enrollment completed for VISTAS PSC study, with topline data expected in Q2 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $133.01

Product mln

Sales

Q3 EPS $0.05

Q3 Net $2.90

Income mln

Q3 $130.40

Operatin mln

g

Expenses

Q3 $2.60

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc ( MIRM ) is $81.50, about 13.1% above its November 3 closing price of $70.85

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)